MEMO FROM THE FUTURE: OPHTHALMOLOGY PRODUCT COMPANIES

The Commoditization of Diagnosis — June 2030

CONFIDENTIAL | The 2030 Report GLOBAL INTELLIGENCE CRISIS SERIES

SUMMARY: THE BEAR CASE vs. THE BULL CASE

Bear case: ophthalmic device and pharma companies face pricing pressure. Bull case: companies with AI-integrated diagnostics and surgical planning became essential infrastructure.

EXECUTIVE SUMMARY

By June 2030, ophthalmology product companies—IOL manufacturers, diagnostic imaging equipment suppliers (Zeiss, Topcon, Alcon), and pharmaceutical companies—have been disrupted by AI in ways distinct from clinician impact. The disruption is primarily margin compression rather than demand destruction. Diagnostic equipment is becoming commoditized. Premium IOLs are losing pricing power. Pharma is facing AI-optimized treatment protocols that reduce injection frequency and drug utilization. Meanwhile, companies investing in AI-enabled surgical planning and robotic systems have gained competitive advantage.

This is a story of winners and losers among major manufacturers.

I. INTRAOCULAR LENS (IOL) MANUFACTURERS: PREMIUM IOL CRISIS

The Premium IOL Pricing Model Before AI

Before AI-driven IOL selection, premium IOLs (multifocal, toric, toric-multifocal) relied on: - Surgeon expertise in refractive targeting - Trial-and-error on which IOL best suited individual patient - Premium pricing because of perceived "specialist selection" - High refractive outcome variability (15-25% of patients dissatisfied with refractive outcomes in multifocal designs)

2026 market mix (US): - Monofocal IOLs: 58% of market, average ASP $400 - Monofocal toric: 18% of market, average ASP $650 - Multifocal: 12% of market, average ASP $900 - Toric-multifocal/extended depth of focus: 12% of market, average ASP $1,200

Premium IOL manufacturers' market position (2026): - Johnson & Johnson (AMO): 32% US market share, ~$2.1B ophthalmology revenue - Alcon: 28% US market share, ~$2.4B ophthalmology revenue - Bausch + Lomb: 22% US market share, ~$1.8B ophthalmology revenue - Carl Zeiss (Meditec): 10% US market share, ~$900M - Staar Surgical: 4% US market share, ~$380M - Other (Abbott Medical Optics, Essilor, regional suppliers): 4%

AI-Optimized IOL Selection: The Disruption

By 2028-2029, AI-powered IOL selection systems launched:

Key platforms: - Alcon ASRS (Alcon Smart Refractive System): Combines preoperative imaging, biometric data, and AI to recommend specific IOL power and design - Johnson & Johnson + Lensar integration: Robotic cataract system with AI IOL optimization - Zeiss VisuMax IOL Assistant: AI-powered IOL selection on Zeiss surgical microscopes - Third-party AI systems: Countless startups (EyeWeek, RxSight, Omni Surgical) built AI-only IOL selection platforms

What AI did: Analyzed thousands of variables (axial length, keratometry, anterior chamber depth, white-to-white distance, lens thickness, patient expectations, visual demands) to recommend optimal IOL choice.

Outcome: Refractive accuracy improved dramatically: - Monofocal targeting within 0.5 D: 96-98% (vs. 88-92% with surgeon judgment) - Multifocal patient satisfaction: 92-95% (vs. 78-85% with surgeon selection) - Toric alignment accuracy: 99%+ (laser-guided robotic systems)

The Pricing Collapse

Here's the critical dynamic: As refractive outcomes improved across all IOL types, patients (and payers) lost justification for premium pricing.

The surgeon's historical pitch (pre-AI): - "You need a multifocal IOL because I'm an expert at selecting them; 80% of my multifocal patients are satisfied" - Patients paid $1,200 for multifocal vs. $400 for monofocal - Payers covered only monofocal; patients paid the premium out of pocket

The AI-era pitch (2029-2030): - "The AI system recommends a standard toric monofocal IOL for your eye. It will give you 96% chance of 20/25 vision without glasses for distance. For near vision, you'll need glasses." - AI demonstrates that multifocal doesn't improve outcomes in this specific patient - Patient and payer ask: "Why pay $1,200 extra for a multifocal if monofocal gives me the same outcome?"

Pricing observed (2029-2030): - Monofocal: $350-400 (stable) - Monofocal toric: $550-600 (down from $650) - Multifocal: $700-850 (down from $900) - Toric-multifocal/EDOF: $950-1,100 (down from $1,200-1,400)

Market mix shift (2029-2030): - Monofocal: 62% of market (up from 58%) - Monofocal toric: 20% (up from 18%) - Multifocal: 9% (down from 12%) - Premium designs: 9% (down from 12%)

Volume Growth Could Not Offset Margin Compression

IOL manufacturers had hoped that: - Volume growth (more cataract surgeries globally) would offset premium IOL pricing decline - Robotic-assisted surgery adoption would create premium "package pricing" (robot + premium IOL)

Reality (2029-2030): - US/Canadian cataract surgery volume actually declined 12-18% (due to AI screening reducing overall ophthalmology volume and surgical center consolidation) - Global cataract volume grew in developing markets, but at lower ASPs - Robotic-assisted surgery adoption was slower than expected (only 22-28% of cases in metro markets; <5% in rural areas)

Financial impact (sample data): - Johnson & Johnson ophthalmology segment revenue: $2.84B (2026) → $2.41B (2030); -15% despite global volume growth - Alcon revenue: $2.36B (2026) → $1.98B (2030); -16% - Bausch + Lomb: $1.82B (2026) → $1.54B (2030); -15%

Margin compression: - IOL gross margins: 72-76% (2026) → 64-68% (2030) - The shift to lower-priced monofocal/toric products and lower ASPs globally squeezed profitability

II. DIAGNOSTIC IMAGING EQUIPMENT: COMMODITIZATION

The OCT Manufacturer Dilemma

OCT (optical coherence tomography) systems had historically been high-margin products: - Zeiss Cirrus OCT, Heidelberg Spectralis, Topcon 3D OCT: $150K-250K per unit - Installed base provided recurring

Bull Case Alternative: Proactive 2025-2026 Strategy

Bull Case (2025-2026 Strategy): Rather than react to these trends, proactive product_companies who invested in specialization, AI integration, and differentiation in 2025-2026 maintained competitive advantage and pricing power by 2030.

revenue (software upgrades, maintenance contracts) - Key ophthalmology practices purchased premium systems for better diagnostic capability

By 2028-2029, AI systems could interpret OCT scans better than humans. The hardware became less important.

The question facing OCT manufacturers: If AI does the interpretation, why pay $200K for a premium OCT system?

Market response (2029-2030): - Premium OCT pricing declined 18-22% - Upgrade cycle slowed (practices didn't need "better" OCTs if AI interpreted them) - Rental/lease models replaced purchase models (lower capital commitment, lower revenue per unit) - Margins compressed as competition increased and ASPs fell

Example: Zeiss Cirrus OCT pricing: - 2026: $220K for base system - 2030: $175K for base system; -20% - Software upgrade fees declined as features became less differentiated

The Shift to "Commoditized Diagnostics"

Large diagnostic imaging players (Zeiss, Topcon, Heidelberg) responded by: 1. Bundling AI with hardware (offer AI interpretation as included software, not separate) 2. Shifting to volume strategy (lower per-unit margin, higher volume) 3. Consolidating around integrated platforms (OCT + fundus imaging + visual fields + AI interpretation bundled together)

By June 2030, OCT was becoming a "commodity" product tier: - High-end OCTs: $150-175K (down from $220K) - Mid-range OCTs: $80-120K (new category, grew rapidly) - Low-cost OCTs: $30-50K (entry-level, used in small practices, urgent care)

Revenue per installed base declined, but volume of units installed increased slightly, resulting in net revenue decline for OCT manufacturers.

III. SURGICAL EQUIPMENT: WINNERS & LOSERS

Robotic-Assisted Cataract Surgery: Moderate Success

Robotic-assisted systems (Bausch + Lomb LENSAR, Johnson & Johnson CATALYS) benefited from AI integration: - AI-optimized surgical planning improved outcomes - Robotic precision reduced complication rates - Surgeons' learning curve shortened with AI guidance

Adoption rates (2029-2030): - Major metro markets (LA, NYC, Chicago, Boston, Dallas): 22-28% of cataract surgeries - Secondary metro markets: 8-15% - Rural markets: <5%

Market size: - Global robotic-assisted catara

ct market: ~$450M (2030), up from $200M (2026) - Bausch + Lomb LENSAR: ~$280M revenue (2030) - Johnson & Johnson CATALYS: ~$150M revenue (2030)

Why adoption was slow: High cost ($1,600-1,800 per-case device fee) limited payer and patient adoption. Outcomes were good but not dramatically better than excellent surgeons with traditional techniques.

Glaucoma Laser & Surgical Equipment: Stable Demand

Glaucoma surgical equipment (selective laser trabeculoplasty, cyclophotocoagulation, glaucoma drainage devices) remained stable: - AI did not disrupt glaucoma surgical decision-making significantly - Demand for glaucoma surgery held steady despite volume decline elsewhere - Margins remained healthy

By June 2030, glaucoma surgical device companies (Alcon, Bausch + Lomb, Ellex, Iridex) maintained relatively stable revenue and margins.

Refractive Surgical Equipment: AI Integration Improved

Excimer laser systems (Alcon LenSAR, Bausch + Lomb VisuMax, Zeiss MEL90) benefited from AI-optimized treatment planning: - AI-planned LASIK/PRK had lower complication rates and better visual outcomes - Surgeons adopted AI-guided planning as standard - Equipment manufacturers bundled AI planning software with systems

LASIK market: Remained small and declining due to AI-powered autorefraction and topography-guided optical retail (see below), but those who purchased systems demanded AI integration.

IV. PHARMACEUTICAL COMPANIES: AI-DRIVEN TREATMENT PROTOCOL OPTIMIZATION

Anti-VEGF Pharma: The Injection Frequency Crisis

Regeneron (Eylea), Roche (Avastin), Novartis (Beovu), and Allergan (Retinal divisions) had built business models on frequent anti-VEGF injections: - Diabetic macular edema (DME): typically 8-12 injections/year - Wet AMD: typically 8-12 injections/year - Retinal vein occlusion (RVO): typically 6-10 injections/year

By 2028-2029, AI-driven treatment optimization systems analyzed: - Patient imaging response patterns - Optimal injection intervals for individual patients - Predictive models for when re-treatment was necessary

The disruption:

EYEPOINT PHARMACEUTICALS AND GOOGLE HEALTH LAUNCH AI-OPTIMIZED ANTI-VEGF TREATMENT PROTOCOL; REAL-WORLD DATA SHOWS 22% FEWER INJECTIONS WITH EQUIVALENT VISUAL OUTCOMES; REGENERON SHARES FALL 7% | Bloomberg, September 2029

Real-world data showed: - AI-guided DME treatment: 6-8 injections/year (vs. 10-12 historically) - AI-guided wet AMD: 6-8 injections/year (vs. 10-12 historically) - Visual outcomes: equivalent or slightly better than physician-guided

Financial impact: - Regeneron Eylea US revenue: $4.3B (2026) → $3.8B (2030); -12% - Roche Avastin (ophthalmic): $1.2B (2026) → $0.9B (2030); -25% (partly due to biosimilar competition, partly due to AI-driven reduced utilization) - Allergan: hit hardest as it lacked strong AI treatment partnerships

Stock market impact: - Regeneron stock: down 18-22% (2028-2030) attributable to ophthalmology revenue decline - Roche: less impact due to diversified portfolio - Allergan/AbbVie: under pressure due to AI-driven reduced pharma utilization

Dry Eye Pharma: Relative Winner

By contrast, dry eye pharmaceutical companies (Bausch + Lomb, Sun Pharma, Aldeyra, Ocuphire) faced less disruption: - Dry eye diagnosis was becoming AI-assisted but not automated - Treatment protocols were individualized (less amenable to standardization) - Growing prevalence of dry eye (screen time, aging population) offset some AI-driven diagnostic efficiency gains

Dry eye pharma revenue remained relatively stable (2026-2030).

Glaucoma Pharma: Stable Market with Slight Headwinds

Glaucoma pharmaceutical market (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors) remained stable, with slight headwinds: - AI screening increased early glaucoma detection (good for pharma market) - But AI-optimized treatment protocols reduced medication utilization slightly - Net effect: stable market with modest growth

V. DIAGNOSTIC TEST COMPANIES: STRUCTURAL DISRUPTION

Optical Coherence Tomography Angiography (OCTA)

OCTA systems (detecting blood flow in retinal layers) were supposed to be a growth market. By 2029-2030, this growth slowed: - AI could interpret OCTA as well as or better than angiographers - Premium pricing for OCTA systems declined - Clinical impact remained valuable but margins compressed

Visual Field (Perimetry) Equipment

Visual field testing is labor-intensive and had been a target for automation: - AI systems analyzed visual fields more reliably than humans for glaucoma progression - But demand for visual fields declined due to AI screening-driven case reduction - Net effect: flat to declining market for perimetry equipment

VI. CANADIAN, UK & AUSTRALIAN PRODUCT MARKET DYNAMICS

Canada: Slower AI Adoption = Longer Premium Pricing Window

Canadian IOL and diagnostic equipment markets saw slower AI adoption due to: - Government budgets for AI infrastructure deployment were constrained - Regulatory approval timelines for AI systems were slower than in US - Premium IOL pricing held up slightly longer (2030 vs. 2029 in US)

By June 2030, Canadian IOL ASPs were 8-12% higher than US, but gap was closing.

UK: NHS Cost Pressure Accelerates Commoditization

The UK National Health Service, facing budget constraints, accelerated adoption of: - Lower-cost diagnostic equipment (premium OCTs were deemed unnecessary) - Commoditized IOLs (NHS trusts specified monofocal/toric IOLs as standard) - Generic anti-VEGF (Avastin preferred over Eylea for cost reasons)

By June 2030, UK diagnostic and IO

L pricing was 20-30% below US levels due to NHS cost pressure.

Australia: Remote Diagnostics Opportunity

Australia's teleophthalmology requirements created niche opportunities: - Portable/mobile diagnostic systems (smartphone-based retinal imaging, handheld OCT) - Remote diagnostic software platforms - These benefited smaller companies but didn't fundamentally reshape the market

VII. WINNERS & LOSERS (JUNE 2030)

Winners:

1. Alcon: Successfully integrated AI into ASRS platform; early mover in robotic-assisted systems. Maintained market share and margins better than competitors.
2. Johnson & Johnson: CATALYS robotic system and AI integration positioned well; strong brand and diverse product portfolio buffered margin compression.
3. Bausch + Lomb: Aggressive acquisition strategy and LENSAR robotic system gave competitive edge.
4. Smaller AI-native companies: EyeWeek, RxSight, Omni Surgical, and others that built AI-first diagnostic platforms gained traction.

Losers:

1. Regeneron: Eylea revenue under pressure; anti-VEGF injection frequency declining due to AI optimization.
2. Roche/Avastin: Biosimilar competition + AI-driven reduced utilization = significant margin pressure.
3. Premium IOL manufacturers with weak AI strategies: Staar Surgical, some regional suppliers faced declining ASPs and market share.
4. OCT manufacturers without integrated AI: Heidelberg Spectralis lost some market share to Zeiss and Topcon with better AI integration.

VIII. IMPLICATIONS & COMPETITIVE DYNAMICS

AI as a Moat for First-Movers

Companies that integrated AI early (Alcon, Zeiss, Topcon) created competitive advantages: - Bundled AI + hardware created switching costs - Data advantages (larger installed base → better training data → better AI models) - Brand positioning as "AI-enabled" attracted practices and patients

By June 2030, the product company market was bifurcating: - Large, integrated platforms (Alcon, J&J, Zeiss, Topcon): maintaining market share through AI bundling - Smaller, AI-native startups: gaining traction in specific niches (AI surgical planning, telemedicine platforms) - Legacy players without AI strategy: losing share and facing M&A or forced combination (Bausch + Lomb acquired Staar's cataract assets in 2029 as a defensive move)

Consolidation Accelerating

By June 2030, ophthalmology product company consolidation was accelerating: - Bausch + Lomb acquiring regional players - Alcon and J&J defending market share through aggressive pricing and bundling - Smaller companies either being acquired or finding niche markets

The "product company consolidation" paralleled the "ophthalmology practice consolidation"—both driven by AI and scale advantages.

IX. FINANCIAL FORECAST (NEXT 5-10 YEARS)

Medium-Term Outlook (2030-2035)

Product companies face a challenging decade: - IOL ASPs will continue to decline as AI-driven commoditization advances - Diagnosti

c equipment will face continued margin pressure - Pharma will face AI-driven treatment protocol optimization reducing utilization - Robotic surgical systems will see adoption increase, but not as rapidly as some investors hoped

Consensus forecast (analyst estimates): - Ophthalmology device/pharma market growth: 2-4% CAGR (2030-2035), well below historical 6-8% - Margin compression: 300-500 basis points across most product categories - Winners: companies with strong AI capabilities, surgical focus, or niche positioning - Losers: companies reliant on premium diagnostic equipment or high-injection-frequency pharma

END OF MEMO

The 2030 Report Global Intelligence Crisis Series | Confidential | June 2030

COMPARISON TABLE: BEAR CASE vs. BULL CASE OUTCOMES

End of Memo

Prepared by: The 2030 Report | Futurism Unit Classification: Speculative Analysis | June 2030 Projection

REFERENCES & DATA SOURCES

1. Bloomberg Ophthalmology Intelligence, 'AI Diagnostic Systems and Retinal Imaging,' June 2030
2. McKinsey Eye Care Services, 'Ophthalmology Practice Consolidation and Consolidators,' May 2030
3. Gartner Healthcare Technology, 'Digital Ophthalmology and Telemedicine Integration,' June 2030
4. IDC Ophthalmology, 'Electronic Health Record Integration and Decision Support AI,' May 2030
5. Deloitte Eye Care, 'Practice Efficiency and Automation in Ophthalmology,' June 2030
6. American Academy of Ophthalmology (AAO), 'Ophthalmology Workforce and Practice Economics,' June 2030
7. Ophthalmology Management Association, 'Practice Consolidation and Private Equity Involvement,' May 2030
8. Journal of Refractive Surgery, 'LASIK and Surgical Innovation Trends,' 2030
9. Eye Care Business Association, 'Retail Optometry and Direct-to-Consumer Models,' June 2030
10. Mergermarket Healthcare, 'Ophthalmology M&A Activity and Multiples,' May 2030
11. Private Equity Eye Care Fund, 'Ophthalmology Consolidation Strategy and Valuations,' June 2030
12. American Society of Cataract and Refractive Surgeons (ASCRS), 'Surgical Innovation and Outcomes,' June 2030